HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,753-1,764 of 4,505
Drug study icon
CompletedEUCTR 2013-001695-38

A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA

This study has finished and is no longer accepting participants.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

Multiple locations, including Dothan
SchizophreniaHistorical research recordAges 13–17
Countries
United States, France, United Kingdom, + 13 others
Sponsor
SUNOVION PHARMACEUTICALS INC.
Drug study icon
CompletedEUCTR 2017-001447-12

A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr...

This study has finished and is no longer accepting participants.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

In Oklahoma City
SchizophreniaHistorical research recordAges 13–17
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
TerminatedEUCTR 2021-003834-34

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop...

This study ended early.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

Multiple locations, including Phoenix
SchizophreniaHistorical research recordAges 18–50
Countries
United States, Bulgaria, Czechia, + 2 others
Sponsor
Neurocrine Biosciences, Inc.
Drug study icon
CompletedACTRN12605000254695

Indicated Prevention of Psychotic Disorders with Low-dose Lithium

Official study title

An open-labeled, parallel-group, single-blinded (rater) pilot study to investigate the neuroprotective effects of of low-dose lithium in young subjects at ultra high risk (UHR) of developing a first-episode psychotic disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaInterventional study
Countries
Sponsor
stanley Medical Research Centre (USA)
Behavioral study icon
CompletedACTRN12616000098437

Staged Treatment in Early Psychosis (STEP): A sequential multistage study (SMART) of interventions for Ultra High Risk (UHR) of psychosis patients.

Official study title

A sequential multistage randomized clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical and/or functional outcomes.

This study has finished and is no longer accepting participants.

In Australia
SchizophreniaInterventional studyAges 12–25
Countries
Australia
Sponsor
Orygen Youth Health
Drug study icon
CompletedACTRN12618000051246

The effect of atropine sulfate 1% administered under the tongue on excessive saliva secretion and drooling caused by clozapine in people with schizophrenia.

Official study title

The effect of sublingual atropine sulfate on the rate of saliva secretion in patients with schizophrenia who are found to have Clozapine-Induced Hypersalivation and/or Drooling

This study has finished and is no longer accepting participants.

Multiple locations, including Camperdown
SchizophreniaInterventional studyAges 18+
Countries
Australia
Sponsor
The University of Sydney

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.